Guardant Health Inc. (GH)
NASDAQ: GH
· Real-Time Price · USD
46.89
-1.98 (-4.05%)
At close: May 02, 2025, 3:59 PM
46.85
-0.09%
After-hours: May 02, 2025, 05:34 PM EDT
-4.05% (1D)
Bid | 45.52 |
Market Cap | 5.79B |
Revenue (ttm) | 774M |
Net Income (ttm) | -416.55M |
EPS (ttm) | -3.39 |
PE Ratio (ttm) | -13.83 |
Forward PE | -19.71 |
Analyst | Buy |
Ask | 48.75 |
Volume | 4,280,282 |
Avg. Volume (20D) | 2,232,374 |
Open | 50.20 |
Previous Close | 48.87 |
Day's Range | 45.52 - 51.38 |
52-Week Range | 18.01 - 52.92 |
Beta | 1.45 |
About GH
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test fo...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Oct 4, 2018
Employees 1,999
Stock Exchange NASDAQ
Ticker Symbol GH
Website https://guardanthealth.com
Analyst Forecast
According to 21 analyst ratings, the average rating for GH stock is "Buy." The 12-month stock price forecast is $55, which is an increase of 17.30% from the latest price.
Stock ForecastsEarnings Surprise
Guardant Health has released their quartely earnings
on Apr 30, 2025:
3 days ago
+3.47%
Guardant Health shares are trading higher after th...
Unlock content with
Pro Subscription
2 days ago
-4.64%
Guardant Health shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sales guidance.